Informations pratiques
Adresse

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France

Standard

Tel : +33 (0)1 42 11 42 11

Urgences

Gustave Roussy n'assure que les urgences des patients pris en charge à l'Institut.
Urgences uniquement : +33 (0)1 42 11 50 00

GUSTAVE ROUSSY
1er centre de lutte contre le cancer en Europe, 3 000 professionnels mobilisés

Service de Biostatistique et d’Epidémiologie

Chef de service
Dr Ellen Benhamou
Tel : + 33 (0)1 42 11 41 44

Bâtiment de Médecine Moléculaire
Rez-de-chaussée

Frise de présentation (bandeau): 
Service de Biostatistique et d’Epidémiologie

Publications 2015 (mise à jour juillet 2015)

1.    Bölling T,Braun-Munzinger G,Burdach S,Calaminus G,Craft A,Delattre O,Deley MC,Dirksen U,Dockhorn-Dworniczak B,Dunst J,Engel S,Faldum A,Fröhlich B,Gadner H,Göbel U,Gosheger G,Hardes J,Hawkins DS,Hjorth L,Hoffmann C,Kovar H,Kruseova J,Ladenstein R,Leuschner I,Lewis IJ,Oberlin O,Paulussen M,Potratz J,Ranft A,Rössig C,Rübe C,Sauer R,Schober O,Schuck A,Timmermann B,Tirode F,van den Berg H,van Valen F,Vieth V,Willich N,Winkelmann W,Whelan J,Womer RB. Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe. Klin Padiatr 2015; 227:108-115.

2.    Ribassin-Majed L,Hill C. Trends in tobacco-attributable mortality in France. Eur J Public Health 2015.

3.    Blanchard P,Lee A,Marguet S,Leclercq J,Ng WT,Ma J,Chan AT,Huang PY,Benhamou E,Zhu G,Chua DT,Chen Y,Mai HQ,Kwong DL,Cheah SL,Moon J,Tung Y,Chi KH,Fountzilas G,Zhang L,Hui EP,Lu TX,Bourhis J,Pignon JP,MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015; 16:645-55.

4.    Lazar V,Rubin E,Depil S,Pawitan Y,Martini JF,Gomez-Navarro J,Yver A,Kan Z,Dry JR,Kehren J,Validire P,Rodon J,Vielh P,Ducreux M,Galbraith S,Lehnert M,Onn A,Berger R,Pierotti MA,Porgador A,Pramesh CS,Ye DW,Carvalho AL,Batist G,Le Chevalier T,Morice P,Besse B,Vassal G,Mortlock A,Hansson J,Berindan-Neagoe I,Dann R,Haspel J,Irimie A,Laderman S,Nechushtan H,Al Omari AS,Haywood T,Bresson C,Soo KC,Osman I,Mata H,Lee JJ,Jhaveri K,Meurice G,Palmer G,Lacroix L,Koscielny S,Eterovic KA,Blay JY,Buller R,Eggermont A,Schilsky RL,Mendelsohn J,Soria JC,Rothenberg M,Scoazec JY,Hong WK,Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget 2015.

5.    Tsao MS,Marguet S,Le Teuff G,Lantuejoul S,Shepherd FA,Seymour L,Kratzke R,Graziano SL,Popper HH,Rosell R,Douillard JY,Le-Chevalier T,Pignon JP,Soria JC,Brambilla EM. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol 2015.

6.    Di Giannatale A,Frezza AM,Le Deley MC,Marec-Bérard P,Benson C,Blay JY,Bui B,Judson I,Oberlin O,Whelan J,Gaspar N. Primary cutaneous and subcutaneous Ewing sarcoma. Pediatr Blood Cancer 2015.

7.    Blanchard P,Bourhis J,Lacas B,Le Teuff G,Michiels S,Pignon JP. [Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives]. Cancer Radiother 2015; 19:198-204.

8.    Selimoglu-Buet D,Wagner-Ballon O,Saada V,Bardet V,Itzykson R,Bencheikh L,Morabito M,Met E,Debord C,Benayoun E,Nloga AM,Fenaux P,Braun T,Willekens C,Quesnel B,Adès L,Fontenay M,Rameau P,Droin N,Koscielny S,Solary E,Groupe Francophone des Myélodysplasies. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 2015; 125:3618-26.

9.    Bonastre J,Marguet S,Lueza B,Michiels S,Delaloge S,Saghatchian M. Reply to v.p. Retèl et Al, d. Gauchan et Al, and C. Rahilly-tierney et Al. J Clin Oncol 2015; 33:1629-30.

10.    Robert C,Sibaud V,Mateus C,Verschoore M,Charles C,Lanoy E,Baran R. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 2015; 16:e181-9.

11.    Hill C,Nicot P,Piette C,Le Gleut K,Durand G,Toussaint B. Estimating the number of sudden cardiac deaths attributable to the use of domperidone in France. Pharmacoepidemiol Drug Saf 2015; 24:543-7.

12.    Strullu M,Thomas C,Le Deley MC,Chevance A,Kanold J,Bertrand Y,Jubert C,Dalle JH,Paillard C,Baruchel A,Lamant L,Michel G,Brugières L. Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. Bone Marrow Transplant 2015; 50:795-801.

13.    Levy A,Azria D,Pignon JP,Delarochefordiere A,Martel-Lafay I,Rio E,Malka D,Conroy T,Miglianico L,Becouarn Y,Malekzadeh K,Leclercq J,Juzyna B,Ezra P,Lemanski C,Deutsch E. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol 2015; 114:415-6.

14.    Dartois L,Gauthier É,Heitzmann J,Baglietto L,Michiels S,Mesrine S,Boutron-Ruault MC,Delaloge S,Ragusa S,Clavel-Chapelon F,Fagherazzi G. A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort. Breast Cancer Res Treat 2015; 150:415-26.

15.    Burdett S,Pignon JP,Tierney J,Tribodet H,Stewart L,Le Pechoux C,Aupérin A,Le Chevalier T,Stephens RJ,Arriagada R,Higgins JP,Johnson DH,Van Meerbeeck J,Parmar MK,Souhami RL,Bergman B,Douillard JY,Dunant A,Endo C,Girling D,Kato H,Keller SM,Kimura H,Knuuttila A,Kodama K,Komaki R,Kris MG,Lad T,Mineo T,Piantadosi S,Rosell R,Scagliotti G,Seymour LK,Shepherd FA,Sylvester R,Tada H,Tanaka F,Torri V,Waller D,Liang Y,Non‐Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev 2015; 3:CD011430.

16.    Gourgou-Bourgade S,Cameron D,Poortmans P,Asselain B,Azria D,Cardoso F,A'Hern R,Bliss J,Bogaerts J,Bonnefoi H,Brain E,Cardoso MJ,Chibaudel B,Coleman R,Cufer T,Dal Lago L,Dalenc F,De Azambuja E,Debled M,Delaloge S,Filleron T,Gligorov J,Gutowski M,Jacot W,Kirkove C,MacGrogan G,Michiels S,Negreiros I,Offersen BV,Penault Llorca F,Pruneri G,Roche H,Russell NS,Schmitt F,Servent V,Thürlimann B,Untch M,van der Hage JA,van Tienhoven G,Wildiers H,Yarnold J,Bonnetain F,Mathoulin-Pélissier S,Bellera C,Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.

17.    Jourdain A,Auperin A,Minard-Colin V,Aladjidi N,Zsiros J,Coze C,Gandemer V,Bertrand Y,Leverger G,Bergeron C,Michon J,Patte C,SFCE LNH Committee. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study. Haematologica 2015; 100:810-7.

18.    Deutsch E,Le Péchoux C,Faivre L,Rivera S,Tao Y,Pignon JP,Angokai M,Bahleda R,Deandreis D,Angevin E,Hennequin C,Besse B,Levy A,Soria JC. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol 2015; 26:1223-9.

19.    de Baère T,Aupérin A,Deschamps F,Chevallier P,Gaubert Y,Boige V,Fonck M,Escudier B,Palussiére J. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015; 26:987-91.

20.    Ezzalfani M,Dugué A,Mollevi C,Pulido M,Bonnetain F,Filleron T,Gal J,Gauthier M,Le Deley MC,Le Tourneau C,Médioni J,Nguyen JM,Chabaud S,Teixeira L,Thivat E,You B,Kramar A,Paoletti X. [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. Bull Cancer 2015; 102:73-82.

21.    Escolano S,Hill C,Tubert-Bitter P. Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach. Vaccine 2015; 33:1017-20.

22.    Ribassin-Majed L,Hill C,Lounes R. Efficacy of vaccination against HPV infection to prevent cervical cancer in France. Public Health 2015; 129:78-81.

23.    Le Teuff G,Abrahamowicz M,Wynant W,Binquet C,Moreau T,Quantin C. Flexible modeling of disease activity measures improved prognosis of disability progression in relapsing-remitting multiple sclerosis. J Clin Epidemiol 2015; 68:307-16.

24.    Faron M,Pignon JP,Malka D,Bourredjem A,Douillard JY,Adenis A,Elias D,Bouché O,Ducreux M. Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. Eur J Cancer 2015; 51:166-76.

25.    Huynh M,Poumeyrol S,Pignon C,Le Teuff G,Zilberstein L. Intramuscular administration of alfaxalone for sedation in rabbits. Vet Rec 2015; 176:255.

26.    Doussau A,Thiébaut R,Geoerger B,Schöffski P,Floquet A,Le Deley MC,Mathoulin-Pélissier S,Rizzo E,Fumoleau P,Le Tourneau C,Paoletti X. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials. Ann Oncol 2015; 26:422-8.

27.    Palussiere J,Lagarde P,Aupérin A,Deschamps F,Chomy F,de Baere T. Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years' experience in 87 patients from two centers. Cardiovasc Intervent Radiol 2015; 38:160-6.

28.    M'kacher R,Girinsky T,Colicchio B,Ricoul M,Dieterlen A,Jeandidier E,Heidingsfelder L,Cuceu C,Shim G,Frenzel M,Lenain A,Morat L,Bourhis J,Hempel WM,Koscielny S,Paul JF,Carde P,Sabatier L. Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure. Radiat Prot Dosimetry 2015; 164:134-7.

29.    Joskin J,de Baere T,Auperin A,Tselikas L,Guiu B,Farouil G,Boige V,Malka D,Leboulleux S,Ducreux M,Baudin E,Deschamps F. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol 2015; 38:372-80.

30.    Tselikas L,Joskin J,Roquet F,Farouil G,Dreuil S,Hakimé A,Teriitehau C,Auperin A,de Baere T,Deschamps F. Percutaneous bone biopsies: comparison between flat-panel cone-beam CT and CT-scan guidance. Cardiovasc Intervent Radiol 2015; 38:167-76.

31.    Martelli N, Billaux M, Borget I, Pineau J, Prognon P, van den Brink H. Introduction of innovative medical devices at French university hospitals: an overview of hospital-based health technology assessment initiatives. Int J Technol Assess Health Care. 2015 Jan;31(1-2):12-8.

32.    Scotte F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. AdvTher. 2015 Feb;32(2):138-47.

33.    Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in thyroid cancer patients: results from the randomized phase III ESTIMABL trial. J Clin Oncol 2015

34.    Bonastre J, Marguet S, Lueza B, Michiels S, Delaloge S, Saghatchian M. Reply to V.P. Retèl et al, D. Gauchan et al, and C. Rahilly-Tierney et al. J Clin Oncol. 2015 May 10;33(14):1629-30.

35.    Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandreis D, Sclumberger M, Borget I, Ducreux M, Baudin E. Post-first line FOLFOX chemotherapy in Grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015 Jun;22(3):289-98

36.    Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F. High Level of Chromosomal Instability in Circulating Tumor Cells of ROS1-Rearranged Non-Small-Cell Lung Cancer. Ann Oncol 2015 Jul;26(7):1408-15

37.    Lepoutre-Lussey C, Caramella C, Bidault F, Déandreis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F, Deschamps F, Nascimento C, Lumbroso J, Guillaud Bataille M, Schlumberger M, Baudin E, Leboulleux S. Screening in asymptomatic SDHx mutation carriers: added value of (18)F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging. 2015 May;42(6):868-76

38.    Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015; 25: 437-44

39.    Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 2015; 25: 386-91.

40.    Rage E, Caër-Lorho S, Drubay D, Ancelet S, Acker A, Laurier D. Mortality analyses in the updated French cohort of uranium miners (1946 – 2007). International Archives of Occupational and Environmental Health 2015 Aug;88(6):717-30.

41.    Drubay D, Caër-Lorho S, Laroche P, Laurier D, Rage E. Mortality from Circulatory System Diseases among French Uranium Miners: A Nested Case-Control Study. Radiation Research 2015;183(5):550-62.

42.    Paoletti X, Ezzalfani M, Le Tourneau C. Requiem for the 3+3 design for phase I trials. Annals of Oncology 2015;26(9):1808-12.

43.    Riviere MK, Le Tourneau C, Paoletti X, Dubois F, Zohar S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Ann Oncol 2015 Apr;26(4):669-74.

44.    Paoletti X, Asselain B, Kamal M, Servant S, Huppé P, Bieche I, Le Tourneau C. Design and statistical principles of the SHIVA trial. Chinese Clinical Oncology (2015).

45.    Paoletti X, Doussau A, Ezzalfani M, Rizzo E, Thiébaut R. Dose finding with longitudinal data: simpler models, richer outcomes. Stat Med. 2015 Jun 24. doi:10.1002/sim.6552. [Epub ahead of print].

46.    Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T., Statistical evaluation of surrogate endpoints with examples from cancer clinical trials, Biom J 2015 [Epub ahead of print].

47.    S Foulon, J B Pingault, B Larroque, M Melchior, B Falissard, S M Côté on behalf of the EDEN Mother–Child Cohort Study Group. Developmental predictors of inattention- hyperactivity from pregnancy to early childhood. PLoS One. 2015 May 4;10(5):e0125996. doi: 10.1371

 

PDF icon> Voir les publications 2014 (document PDF)

PDF icon> Voir les publications 2013 (document PDF)

 

 

Catégorie de la page: